Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRĪ± Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.

Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF.

Mol Cancer Ther. 2018 Dec;17(12):2665-2675. doi: 10.1158/1535-7163.MCT-17-1215. Epub 2018 Sep 27.

PMID:
30262588
2.

Site-Specific Conjugation to Native and Engineered Lysines in Human Immunoglobulins by Microbial Transglutaminase.

Spidel JL, Vaessen B, Albone EF, Cheng X, Verdi A, Kline JB.

Bioconjug Chem. 2017 Sep 20;28(9):2471-2484. doi: 10.1021/acs.bioconjchem.7b00439. Epub 2017 Sep 6.

PMID:
28820579
3.

Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Spidel JL, Albone EF, Cheng X, Vaessen B, Jacob S, Milinichik AZ, Verdi A, Kline JB, Grasso L.

MAbs. 2017 Aug/Sep;9(6):907-915. doi: 10.1080/19420862.2017.1330734. Epub 2017 May 25.

4.

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Albone EF, Spidel JL, Cheng X, Park YC, Jacob S, Milinichik AZ, Vaessen B, Butler J, Kline JB, Grasso L.

Cancer Biol Ther. 2017 May 4;18(5):347-357. doi: 10.1080/15384047.2017.1312232. Epub 2017 Apr 10.

5.

Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.

Jouanneau M, McClary B, Reyes JC, Chen R, Chen Y, Plunkett W, Cheng X, Milinichik AZ, Albone EF, Liu JO, Romo D.

Bioorg Med Chem Lett. 2016 Apr 15;26(8):2092-7. doi: 10.1016/j.bmcl.2016.02.051. Epub 2016 Feb 23.

6.

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, Park YC, Albone EF, Jacob S, Goserud MT, Martinez BP, Chao Q, Zhou Y, Nicolaides NC, Kline JB, Grasso L.

Cancer Biol Ther. 2013 Nov;14(11):1032-8. doi: 10.4161/cbt.26106. Epub 2013 Aug 28.

7.

Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.

Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH.

Nucl Med Biol. 2011 Nov;38(8):1119-27. doi: 10.1016/j.nucmedbio.2011.05.003. Epub 2011 Jul 7.

8.

Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury.

Matsubara M, Kanemoto S, Leshnower BG, Albone EF, Hinmon R, Plappert T, Gorman JH 3rd, Gorman RC.

J Surg Res. 2011 Jan;165(1):38-45. doi: 10.1016/j.jss.2009.03.016. Epub 2009 Apr 16.

9.

Characterization of antibodies to CA 125 that bind preferentially to the cell-associated form of the antigen.

Singleton J, Guillen DE, Scully MS, Xue J, Moffet J, Chen C, Patel SR, Schilling A, Corisdeo S, Yang Q, Wang B, Soltis DA, Albone EF.

Tumour Biol. 2006;27(3):122-32. Epub 2006 Apr 11.

PMID:
16612145
10.

Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.

Masters GR, Berger MA, Albone EF.

Gynecol Oncol. 2006 Sep;102(3):462-7. Epub 2006 Jan 24.

PMID:
16434088
11.

Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer.

Berger MA, Masters GR, Singleton J, Scully MS, Grimm LG, Soltis DA, Albone EF.

Cancer Biother Radiopharm. 2005 Dec;20(6):589-602.

PMID:
16398611
12.

Molecular cloning and characterization of the gene encoding rat submandibular gland apomucin, Mucsmg.

Albone EF, Hagen FK, Szpirer C, Tabak LA.

Glycoconj J. 1996 Oct;13(5):709-16.

PMID:
8909997
13.

Molecular cloning of a rat submandibular gland apomucin.

Albone EF, Hagen FK, VanWuyckhuyse BC, Tabak LA.

J Biol Chem. 1994 Jun 17;269(24):16845-52.

Supplemental Content

Loading ...
Support Center